Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WTF? They're getting bonus shares because they were incompetent enough to cause a trading halt? Am I reading this correctly?
The market loves our new scientist!
I publicly posted I was waiting for $0.30. Look it up. I got too greedy. I didn't sell at $2.50+ either because I believed in the business model (and was greedy then too).
I just got the PR via email, which is funny they wait 12 hours to send the email out to people who took the time to sign up for their email update.
Anyway, the funny part about re-reading the PR is they say Rene is removed from the "day to day" activities. Ummm...like what? Being a Chief FINANCIAL Officer who doesn't file FINANCIAL documents? Ensuring $0.00 of revenue for the entire 2016 calendar year? What about all the patented formulae for nutraceutical products? South Korea? China?
I would love for this to get to dollar land, but it just ain't happening.
Yes, I read it. Did you?
A lot of contingencies in that Memo. A long time poster here mentioned the clown show known as Abattis management already fumbled away the opportunity.
I have no idea what you're trying to imply with this remark. But maybe that was your plan, to get a reply?
I'm not asking these questions to challenge HC, only to raise a point to current and potential investors about the concept "barriers to entry". The value to the CSL is there were only 18 companies approved when Abattis PR'd the license. My point was...if this so lucrative, and apparently you don't even need a scientist or functional lab to get a license, then how long can Abattis truly capitalize on this opportunity before other more respected cannabis companies jump into the testing market? And will NV even be operational in time to fully capitalize on "first mover status", to gain customers, establish trust, enjoy premiums on price, etc.
Only chance IMO is to get purchased by an LP who wants to make a long term investment in Quality Control to reduce their incremental cost per batch. I suppose if Experion executes their MMPR then Abattis can enjoy 25% of it, but that is a long ways off.
I'm just trying to be objective.
Did they not have any scientists on board during the approval process? If not, how did they justify to HC they should be granted a license? I'm confused as to how they were vetted and awarded a prestigious license if (a). They had no scientist on the team, and (b). The lab wasn't even set up yet.
If I'm negative, it's just to offset the overly optimistic green BS-ers. None of them are objective. A true discussion board should present both sides of an argument. I've been here long enough to be skeptical because nothing they have promoted has ever happened.
And I don't trust Rene. Why is he on the Board of Directors now? How was he not in the board before this?
Trust me, I just need this to get to a quarter and I'll take my losses and move on.
Ok, great...they hired somebody. That requires a press release?
What a joke. CFO, COO, and interim CEO decided to join the Board of Directors? Like he wasn't in a leadership role already? How many more shares does he get for this?
Those revenues will not be large at all. We've covered that already. It's just one more thing to promote.
It's only under the radar because 3 years ago everyone knew them and they failed. They still haven't accomplished anything. And they only own 75% of Northern Vine. A true embarrassment of a company. I was waiting to sell at $0.30 but maybe now I need to sell at $0.20 with the next pump.
Just waking up in your side of the world?
What a disgrace. I hate Rene.
Abattis is the king of fluff PR. They issue PR's about newspaper articles.
There is nothing STRONG about Abattis. Not leadership. Not execution. Certainly not revenue.
Could be an interesting day! Likely dumpfest, right?
It's not up to date, since it only says NV has applied for a license. They received their license months ago.
No, you're a liar. Na na na na!
I actually did lie, I've only been here 3 years not 4. Lost track of time. This company sounded very promising but has proven they have no interest in doing anything worthwhile. They change directions every few months. They do not execute what they say they're going to do. They cant even file their financials or hold a shareholder meeting.
You can check my history, I used to be a believer. I spoke to some of their old Directors on the phone, they sent me sample products which I still have in my basement. I contacted the CO doctor that I thought was going to get this ticker into multi-dollar land, only to learn from him directly that most everything that was PR'd was BS.
The volatility here is fantastic, plenty of money to be made flipping, but it's not an investment. That's my only point. Good luck.
I was ready to sell at $0.30 but of course it didn't make it there. I agree and respect your insight into Abattis, I know you've had logical takes the past few years. It's all about the extraction and Controlled Substance License. All of the nutraceutical PR's and focus on Asian markets...yet no revs. Still.
I'm too far down to sell. Going for a Hail Mary.
It's a horrible company. I recommend moving on.
Yeah, likely after the next .com bubble there will be another Green Rush.
No, the original run was sector wide, nobody understood HC's expectations, which were constantly evolving. Abattis was swept up in the famous Green Rush.
Why do you say 15? Abattis' own PR's show 18, and that was a while ago. Could easily be more by now. Seems you're the one reaching.
Relatively speaking, 18 test locations for 30-ish LP's is a lot. Minimal chance for true increase in SP due to testing, as explained.
In approximately 40 days they might possibly be one of 18 companies that can test weed.
They predicted a trading halt due to incompetence, and it happened.
I forgot one more very important thing here: Abattis only owns 75% of Northern Vine! So reduce those projections by 25%.
Seems Experion may have a decent management team because the only topics making progress have their hands in it. Abattis' wholly owned subs are just issuing PR's about "potential" markets ... FOUR YEARS RUNNING!
I know how to read, I just don't believe their PR's.
You're probably right. NV has a 1/18 chance (5.5%) to get a little bit of business, assuming they actually execute something and get the lab in place. That is the key. They have not executed anything correctly in 4 years.
They will, and they're also going to state on the same PR that HC requires testing, and the market for weed will be $20B, blah blah blah. Bunch of hacks.
Those emails were right....
I agree, but if you do some math you will see we aren't going to the moon on a controlled substance license for testing. I thought I was generous when I said $5k/week in revenue. How many LP's are there now, around 30+? Those 30+ companies have 18 labs to choose from. Competition means lower prices and lower margins.
The big money is pharma, like GW. Abattis needs to get their license amended for this step. I believe I posted the response from HC a while back. That process is not going to be helped my Rene's failure to operate like a legit company. Unfortunately it could still hurt that Withrow was Tweeting out overly optimistic messages like "almost there", which got his hand slapped and forced the big HC / CSE (?) warning letter.
The nutraceutical product line will face an uphill battle without the amended license for export. There are TONS of other companies in China and South Korea that sell pills that claim to help XYZ. They need to put CBD in there to stand out.
Best chance, IMO, is to get the license amended and sell out to an LP with deep pockets.
Either that or hemp water! LOL, HTH.
Sorry kids, I have a life. It's a Saturday night and I was out with the family.
1. It's not feasible to get 7 figure revenue here. You just proved my point. $100 per test? So they need to test 10,000 samples per year to get to 7 figures. Doubt that's possible. I was willing to say $1000/test but I was too optimistic by 10x.
2. If they buy the remaining 75% of Experion in mid-2018 (best case), that will double the share count, least.
3. I do have shares, been posting here since 2013, I'm the only realistic guy here. Down $20k. I was going to sell at $0.30 but wish I sold at $0.25.
4. Whichever of you guys are begging to buy "my" shares, go buy someone else's. They're cheap. Was it you that said "I'll keep buying to $1.00?" What a joke.
5. This company has posted plan after plan, market opportunity after market opportunity, and still had $0.00 in revenue this past year while continuing to hand out $1M + in management and consulting fees. They have two Finance guys in top tier of management and still can't file their financials on time. Incompetent, for sure.
Anyone looking at this stock objectively can smell you two a mile away. Unfortunately in 2013 my nose was stuffed up and my sense of smell was not as keen.
That's a positive development, no doubt. But realistically it is a 2018 catalyst for something they only own 25% of.
You guys are too funny.
Say they test a batch per week for 5 different LP's, an optimistic amount of repeat business IMO.
I have no idea what they would charge, but let's just say it's $500 per batch. That's $2500 per week in revs, or $130,000 per year. Heck, I'll give you $1,000 per batch = $5,000 per week = $260,000 per year.
Pretend they have a 20% net margin which is pretty darn aggressive. In this scenario it is $52,000 per year in net profit, which is less than $0.0004 earnings per share considering 135M in shares.
A company like, say, Netflix (heard of them?) had EPS of $0.43 in 2016 with a share price $143.25 which is a multiplier of 333 times EPS.
If the market accepts Abattis like they do with Netflix (don't laugh!), share price would be around $0.133.
That means right now we are over-valued at $0.135 pps.
Facebook has a ratio of only 38.8 which values Abattis around $0.015.
The company filed their annual report a couple weeks late and you bust out BOOM GOES THE DYNAMITE!!! On this board, the only acceptable use of caps is LOL, HTH!
WTF are you talking about? $0.00 revenue and millions more to management and consultants. Shorts are doing pretty well here, IMO.
(sigh)....of course I didn't.
Mike left years ago...don't blame him.
The one constant is Rene. He's lining his pockets.
Latest news is they have a CFO and a General Manager of Finance, and apparently neither one of them know how to file their reports on time. Not sure how complicated things can be if they have $12 of revenue, but evidently those two clowns have to crawl out from behind their mountain of shares, pick up the phone, and hire another consultant to do their jobs. Or Mr. David will copy+paste a link from Globe and say how well positioned Abattis is to capitalize on a $20B market, then fail to do a single thing to generate revenue from it. What a hack.
I'm pretty sure Mike Withrow is no longer associated with Arcturus. Too lazy to double check and post link but I recall reading it a while ago.
Yes.
SFP might be someone in the know.
I think we are all confused about the action. How can incompetent management team blow financial audit and shareholder meeting? Nobody is this stupid. Something happening and I doubt it it good.